378 related articles for article (PubMed ID: 9242525)
1. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
[TBL] [Abstract][Full Text] [Related]
2. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
[TBL] [Abstract][Full Text] [Related]
3. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
4. [Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].
Takeuchi M
Gan To Kagaku Ryoho; 2006 Mar; 33(3):397-401. PubMed ID: 16531727
[TBL] [Abstract][Full Text] [Related]
5. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
[TBL] [Abstract][Full Text] [Related]
7. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
9. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
[TBL] [Abstract][Full Text] [Related]
10. Tamibarotene.
Miwako I; Kagechika H
Drugs Today (Barc); 2007 Aug; 43(8):563-8. PubMed ID: 17925887
[TBL] [Abstract][Full Text] [Related]
11. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
Advani SH; Nair R; Bapna A; Gladstone B; Kadam P; Saikia TK; Parekh PM; Gopal R; Nair CN
Am J Hematol; 1999 Feb; 60(2):87-93. PubMed ID: 9929098
[TBL] [Abstract][Full Text] [Related]
12. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid.
Shinjo K; Takeshita A; Ohnishi K; Sakura T; Miyawaki S; Hiraoka A; Takeuchi M; Tomoyasu S; Wakita H; Ata K; Fukutani H; Ueda R; Ohno R;
Int J Hematol; 2000 Dec; 72(4):470-3. PubMed ID: 11197214
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
15. Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid.
Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Ueda R; Ohno R; Harada M
Br J Haematol; 1997 Apr; 97(1):137-40. PubMed ID: 9136955
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia.
Visani G; Tosi P; Cenacchi A; Manfroi S; Gamberi B; Ottaviani E; Tura S
Leuk Lymphoma; 1994 Sep; 15(1-2):143-7. PubMed ID: 7858492
[TBL] [Abstract][Full Text] [Related]
17. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
18. [Retinoid therapy for autoimmune diseases].
Fukasawa H; Kagechika H; Shudo K
Nihon Rinsho Meneki Gakkai Kaishi; 2006 Jun; 29(3):114-26. PubMed ID: 16819260
[TBL] [Abstract][Full Text] [Related]
19. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases.
Fenaux P; Castaigne S; Dombret H; Archimbaud E; Duarte M; Morel P; Lamy T; Tilly H; Guerci A; Maloisel F
Blood; 1992 Nov; 80(9):2176-81. PubMed ID: 1421389
[TBL] [Abstract][Full Text] [Related]
20. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
